Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific director transaction rather than a financial performance report.
Material Changes
The filing details a specific transaction under the Company's Annual Investment Plan:
- Director: Dr M M Slaoui
- Transaction Date: 19 March 2012
- Shares Acquired: 2,115 Ordinary Shares
- Exercise Price: 1,424.25 pence per Ordinary Share
- Notification Date: 21 March 2012
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the director's share transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the exercise price of 1,424.25 pence against the market price on 19 March 2012 to assess the economic value of the award.
- Confirm the total shareholding of Dr M M Slaoui post-transaction to evaluate potential voting power or insider exposure.
- Review the terms of the Annual Investment Plan to understand the vesting and exercise conditions applicable to this award.